PathAI

Overview

PathAI provides AI-powered pathology solutions designed to improve patient outcomes through advanced analytics and digital pathology workflows. The company offers a platform and a suite of AI algorithms for biopharma, laboratories, and clinicians, focusing on biomarker discovery, drug development, and enhanced diagnostic capabilities.

Key Features

• AISight Digital Pathology Platform — A cloud-native, open platform for enterprise workflow, case management, and image management in digital pathology.
• AI Product Solutions — A menu of AI algorithms including ArtifactDetect, TumorDetect, AIM-Tumor Cellularity, and PathAssistDerm for various histopathology assessments.
• Biomarker Quantification Suite — AI products like AIM-PD-L1 and AIM-IHC Breast Panel for automated and reproducible biomarker scoring.
• Translational Research Services — Tools to transform pathology samples into structured insights for oncology and immunology research and drug development.
• Clinical Development Services — Algorithms and lab services for biomarker and drug discovery in areas such as liver, IBD, and Celiac diseases.
• Precision Pathology Network — A network providing access to board-certified pathologists for research and development efforts.

Who It's For

PathAI's solutions are designed for biopharmaceutical companies engaged in drug and diagnostic development, as well as anatomic pathology institutions including academic medical centers, reference laboratories, and health systems. The platform supports pathologists, researchers, and clinical development teams seeking to integrate AI into their workflows for enhanced efficiency and precision.

Notable Strengths

PathAI's strength lies in its extensive AI algorithm menu, which covers a broad range of pathology assessments for translational research, clinical development, and digital pathology. The company also leverages a proprietary network of over 450 board-certified pathologists, contributing to the training and validation of its AI algorithms with over 32.5 million annotations. Its AISight Dx platform has received FDA 510(k) clearance and CE-IVDR marking, indicating regulatory validation for primary diagnosis.